Eczema
Drug research and approvals for eczema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 186 studies of eczema are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 186
- Trials authorized in Canada: 1
- FDA orphan approvals: 1
- EU medicines: 1
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- The LITTLE OWLS Study (in German: "Kleine Eulen OWL"): Exploring the Early-life Microbiome Development and Physical and…NCT07934654 · Not reported · Bielefeld University · starts Mar 1, 2024
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNCT07916480 · Phase 3 · Arcutis Biotherapeutics, Inc. · starts Oct 30, 2026
- A Study for AR100DP1 in Mild to Moderate Atopic DermatitisNCT07914088 · Phase 2 · Arjil Pharmaceuticals LLC · starts Oct 21, 2026
- Observational Analytical Validation Study of the Replior ScratchSenseNCT07909967 · Not reported · Replior AB · starts Oct 12, 2026
- ADBest TREAT RegistryNCT07904546 · Not reported · Universitätsklinikum Hamburg-Eppendorf · starts Jan 1, 2023
- Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With…NCT07895615 · Phase 2 · Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · starts Oct 1, 2026
- PRA-216 Atopic Dermatitis Safety and Efficacy StudyNCT07810777 · Phase 2 · Prana Therapies Inc · starts Sep 17, 2026
- Changes in Skin Myco- and Microbiome After Lebrikizumab TreatmentNCT07807228 · Not reported · University Hospital Bispebjerg and Frederiksberg · starts Jun 5, 2025
Approved 15
- AlitretinoinRetinoid receptor agonist
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- DupilumabInterleukin-4 receptor subunit alpha antagonist
- AbrocitinibTyrosine-protein kinase JAK1 inhibitor
- PimecrolimusFK506-binding protein 1A inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- TetracyclineBacterial 70S ribosome inhibitor
- Cromolyn
- LebrikizumabInterleukin-13 inhibitor
- TralokinumabInterleukin-13 inhibitor
- CrisaborolePhosphodiesterase 4 inhibitor
- NemolizumabInterleukin-31 receptor subunit alpha inhibitor
- Povidone-iodine
- Isopropyl alcohol
Phase 3 12 of 14
- DelgocitinibJanus Kinase (JAK) inhibitor
- AzathioprineAmidophosphoribosyltransferase inhibitor
- CyclosporineCyclophilin A modulator
- GentamicinBacterial 70S ribosome inhibitor
- Polymyxin bCell outer membrane inhibitor
- ClioquinolZinc chelating agent
- CetirizineHistamine H1 receptor antagonist
- DesloratadineHistamine H1 receptor antagonist
- LevocetirizineHistamine H1 receptor antagonist
- Benzocaine
- Clobetasone butyrate
- Alcohol
Phase 2 12 of 13
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- LoperamideMu opioid receptor agonist
- CalcipotrieneVitamin D receptor agonist
- PrednicarbateGlucocorticoid receptor agonist
- SulfamethoxazoleBacterial dihydropteroate synthase inhibitor
- TrimethoprimBacterial dihydrofolate reductase inhibitor
- CephalexinBacterial penicillin-binding protein inhibitor
- ApremilastPhosphodiesterase 4 inhibitor
- OctenidineAntiseptic
- AmlitelimabTumor necrosis factor ligand superfamily member 4 inhibitor
- CG-400549Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor
- Boric acid
Phase 1 or earlier 1
How its trials ended
1,154 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 284 whose ending is known, 52% met their primary endpoint, 3% missed it and 45% stopped early.
- Completed, result not reported53646%
- Ongoing23420%
- Met its primary endpoint14713%
- Status unknown1009%
- Stopped: other or unclear605%
- Stopped: lack of efficacy212%
- Stopped: enrollment or feasibility212%
- Stopped: sponsor or business decision192%
- Missed its primary endpoint91%
- Stopped: funding71%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| May 4, 2023 | A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with…Adtralza (tralokinumab) | LEO Pharma | Closed |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| May 2, 2005 | CNJ-016Treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination: Eczema vaccinatum… | Cangene Corporation | Approved |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 19, 2024 | AnzupgoDelgocitinib | LEO Pharma A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA